Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Trastuzumab × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

33 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

Phase 2 Recruiting

185 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

Phase 2 Unknown

100 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02000882 2022-02-07

STAR Cape+BKM120 MBC With Brain Met

Phase 2 Completed

10 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02260531 2021-05-20

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Phase 2 Completed

36 enrolled 19 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

I-SPY

BIS-Program

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

RESPONSE

NeoPATH

STAR Cape+BKM120 MBC With Brain Met

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases